WuXi PharmaTech Reports 29% Rise in Q2 Revenues
publication date: Aug 14, 2012
Continuing a history of strong earnings reports, WuXi PharmaTech, China's largest CRO/CMO, announced record results for Q2. In fact, the second quarter was the first time its China revenues exceeded $100 million in a single three-month period. In total, the company’s Q2 revenues climbed 29% to $130 million. For historical reference, that was more than four times its results from five years ago, at the time WuXi completed its 2007 IPO. Because the first half of the year was so strong, WuXi raised its 2012 guidance to just under $500 million. More details....
Stock Symbol: (NYSE: WX)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.